PortalPublikationenImpact of chronic graft-versus-host-disease on intensive car...

Impact of chronic graft-versus-host-disease on intensive care outcome in allogeneic hematopoietic stem cell recipients

Standard

Impact of chronic graft-versus-host-disease on intensive care outcome in allogeneic hematopoietic stem cell recipients. / Lueck, Catherina; Tzalavras, Asterios; Wohlfarth, Philipp; Meedt, Elisabeth; Kiehl, Michael; Turki, Amin T; Hoeper, Marius M; Eder, Matthias; Cserna, Julia; Buchtele, Nina; Wolff, Daniel; Schellongowski, Peter; Hämatologie, hämos; Liebregts, Tobias.

in: BONE MARROW TRANSPL, Jahrgang 58, Nr. 3, 03.2023, S. 303-310.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Lueck, C, Tzalavras, A, Wohlfarth, P, Meedt, E, Kiehl, M, Turki, AT, Hoeper, MM, Eder, M, Cserna, J, Buchtele, N, Wolff, D, Schellongowski, P, Hämatologie, H & Liebregts, T 2023, 'Impact of chronic graft-versus-host-disease on intensive care outcome in allogeneic hematopoietic stem cell recipients', BONE MARROW TRANSPL, Jg. 58, Nr. 3, S. 303-310. https://doi.org/10.1038/s41409-022-01875-4

APA

Lueck, C., Tzalavras, A., Wohlfarth, P., Meedt, E., Kiehl, M., Turki, A. T., Hoeper, M. M., Eder, M., Cserna, J., Buchtele, N., Wolff, D., Schellongowski, P., Hämatologie, H., & Liebregts, T. (2023). Impact of chronic graft-versus-host-disease on intensive care outcome in allogeneic hematopoietic stem cell recipients. BONE MARROW TRANSPL, 58(3), 303-310. https://doi.org/10.1038/s41409-022-01875-4

Vancouver

Lueck C, Tzalavras A, Wohlfarth P, Meedt E, Kiehl M, Turki AT et al. Impact of chronic graft-versus-host-disease on intensive care outcome in allogeneic hematopoietic stem cell recipients. BONE MARROW TRANSPL. 2023 Mär;58(3):303-310. https://doi.org/10.1038/s41409-022-01875-4

Bibtex

@article{aa3ad5a129394366a063dee401bf5494,
title = "Impact of chronic graft-versus-host-disease on intensive care outcome in allogeneic hematopoietic stem cell recipients",
abstract = "Chronic graft-vs-host-disease (cGvHD) is the most relevant long-term complication after allogeneic stem cell transplantation (HSCT) with major impact on non-relapse mortality, but data on intensive care unit (ICU) outcome are missing. In this retrospective, multicenter study we analyzed 174 adult HSCT recipients with cGvHD requiring intensive care treatment. Skin, pulmonary, liver, and intestinal involvement were present in 76.7%, 47.1%, 38.1% and 24.1%, respectively, and a total of 63.2% had severe cGvHD. Main reasons for ICU admission were respiratory failure (69.7%) and sepsis (34.3%). Hospital- and 3-year OS rates were 51.7% and 28.6%, respectively. Global severity of cGvHD did not impact short- and long-term survival. However, patients with severe liver cGvHD or the overlap subtype had a reduced hospital survival, while severe pulmonary cGvHD was associated with worse long-term survival. In multivariate analysis need for invasive ventilation (HR 1.08 (95% CI 1.02-1.14)) or hemodialysis (HR 1.73 (95% CI 1.14-2.62)) and <1 year since HSCT (HR 1.56 (95% CI 1.03-2.39)) were independently associated with a poorer survival. While the global severity of cGvHD does not per se affect patients' survival after intensive care treatment, pre-existing severe hepatic, intestinal or pulmonary cGvHD is associated with worse outcomes.",
keywords = "Adult, Humans, Retrospective Studies, Graft vs Host Disease/etiology, Bronchiolitis Obliterans Syndrome, Critical Care, Hematopoietic Stem Cell Transplantation/adverse effects",
author = "Catherina Lueck and Asterios Tzalavras and Philipp Wohlfarth and Elisabeth Meedt and Michael Kiehl and Turki, {Amin T} and Hoeper, {Marius M} and Matthias Eder and Julia Cserna and Nina Buchtele and Daniel Wolff and Peter Schellongowski and h{\"a}mos H{\"a}matologie and Tobias Liebregts",
note = "{\textcopyright} 2022. The Author(s).",
year = "2023",
month = mar,
doi = "10.1038/s41409-022-01875-4",
language = "English",
volume = "58",
pages = "303--310",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "3",

}

RIS

TY - JOUR

T1 - Impact of chronic graft-versus-host-disease on intensive care outcome in allogeneic hematopoietic stem cell recipients

AU - Lueck, Catherina

AU - Tzalavras, Asterios

AU - Wohlfarth, Philipp

AU - Meedt, Elisabeth

AU - Kiehl, Michael

AU - Turki, Amin T

AU - Hoeper, Marius M

AU - Eder, Matthias

AU - Cserna, Julia

AU - Buchtele, Nina

AU - Wolff, Daniel

AU - Schellongowski, Peter

AU - Hämatologie, hämos

AU - Liebregts, Tobias

N1 - © 2022. The Author(s).

PY - 2023/3

Y1 - 2023/3

N2 - Chronic graft-vs-host-disease (cGvHD) is the most relevant long-term complication after allogeneic stem cell transplantation (HSCT) with major impact on non-relapse mortality, but data on intensive care unit (ICU) outcome are missing. In this retrospective, multicenter study we analyzed 174 adult HSCT recipients with cGvHD requiring intensive care treatment. Skin, pulmonary, liver, and intestinal involvement were present in 76.7%, 47.1%, 38.1% and 24.1%, respectively, and a total of 63.2% had severe cGvHD. Main reasons for ICU admission were respiratory failure (69.7%) and sepsis (34.3%). Hospital- and 3-year OS rates were 51.7% and 28.6%, respectively. Global severity of cGvHD did not impact short- and long-term survival. However, patients with severe liver cGvHD or the overlap subtype had a reduced hospital survival, while severe pulmonary cGvHD was associated with worse long-term survival. In multivariate analysis need for invasive ventilation (HR 1.08 (95% CI 1.02-1.14)) or hemodialysis (HR 1.73 (95% CI 1.14-2.62)) and <1 year since HSCT (HR 1.56 (95% CI 1.03-2.39)) were independently associated with a poorer survival. While the global severity of cGvHD does not per se affect patients' survival after intensive care treatment, pre-existing severe hepatic, intestinal or pulmonary cGvHD is associated with worse outcomes.

AB - Chronic graft-vs-host-disease (cGvHD) is the most relevant long-term complication after allogeneic stem cell transplantation (HSCT) with major impact on non-relapse mortality, but data on intensive care unit (ICU) outcome are missing. In this retrospective, multicenter study we analyzed 174 adult HSCT recipients with cGvHD requiring intensive care treatment. Skin, pulmonary, liver, and intestinal involvement were present in 76.7%, 47.1%, 38.1% and 24.1%, respectively, and a total of 63.2% had severe cGvHD. Main reasons for ICU admission were respiratory failure (69.7%) and sepsis (34.3%). Hospital- and 3-year OS rates were 51.7% and 28.6%, respectively. Global severity of cGvHD did not impact short- and long-term survival. However, patients with severe liver cGvHD or the overlap subtype had a reduced hospital survival, while severe pulmonary cGvHD was associated with worse long-term survival. In multivariate analysis need for invasive ventilation (HR 1.08 (95% CI 1.02-1.14)) or hemodialysis (HR 1.73 (95% CI 1.14-2.62)) and <1 year since HSCT (HR 1.56 (95% CI 1.03-2.39)) were independently associated with a poorer survival. While the global severity of cGvHD does not per se affect patients' survival after intensive care treatment, pre-existing severe hepatic, intestinal or pulmonary cGvHD is associated with worse outcomes.

KW - Adult

KW - Humans

KW - Retrospective Studies

KW - Graft vs Host Disease/etiology

KW - Bronchiolitis Obliterans Syndrome

KW - Critical Care

KW - Hematopoietic Stem Cell Transplantation/adverse effects

U2 - 10.1038/s41409-022-01875-4

DO - 10.1038/s41409-022-01875-4

M3 - SCORING: Journal article

C2 - 36496524

VL - 58

SP - 303

EP - 310

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 3

ER -